Member Info for thevid

Put my mind at rest for sure.

I don`t think it will be long before we snap up Msys either.

Spin off with a Nasdaq listing please.

Poor old Muggs.

Good reminder of whats possible.

Velcade

Company: Takeda

Disease: Multiple Myeloma & Mantle Cell Lymphoma

Bortezomib, sold under the brand name Velcade, is a targeted therapy co-developed by Millennium/Takeda and Janssen Pharmaceutical, to treat adults with multiple myeloma (a type of blood cancer). Additionally, it is prescribed to treat adults with mantle cell lymphoma (a cancer of the lymph nodes). In the US, the Millennium is holding the rights for the commercialization of the drug, while Janssen is responsible for commercialization in Europe and the rest of the world. In Japan, it is co-promoted by both Takeda Pharmaceutical Company Limited and Janssen Pharmaceutical. Over the years, Velcade is one of the high revenue-generating drugs for Takeda.

The drug was approved first on May 13, 2003. Along with the US, it is currently approved in 53 countries for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior treatment. Additionally, it is approved in more than 90 countries for the treatment of patients with multiple myeloma (MM). The patent for Velcade is expected to expire this year.

Velcade generated significant revenue from the US healthcare market. In 2021, Velcade yielded about $920 million in the U.S. In the last quarter of 2021, Velcade dragged in nearly 24.1 billion yen ($210 million) from the US market.

Several pharma giants over the years were looking to make Velcade generic and have stimulated lawsuits from Takeda. In 2015, a U.S. judge in Delaware termed the patent as invalid, citing the compound it covers was “the inherent result of an obvious process.” In 2017, Takeda won an appeals court that had termed the patent valid and extended the Velcade patent protections till 2022.

Pharma companies are actively looking forward to tentative approvals for the Velcade generic. Currently, pharma and biotech companies such as Teva, Mylan, and Sandoz (Novartis AG), Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, and Wockhardt Ltd, are in the process to get approval for Velcade generic.

Don`t know why cut out sl uth :)

Good ****hing trils. I think you could be spot on.

Never knew this.
https://www.leeds.ac.uk/news-working-business/news/article/2820/university-spin-outs-join-forces-in-1-5-million-acquisition

https://www.sigmaaldrich.com/GB/en/product/mm/mabs1918

Little article from 2 weeks ago on how Cytiva helped us with LFD.

Chris adds, “For instance, recently, we have been working with a Dx company that were developing a saliva-based lateral flow device. The company needed to produce and purify affimers — small proteins that bind to target antibodies — for their device. Ultimately, they chose to make the affimers in a ReadyToProcess WAVE™ bioreactor and purify them using an ÄKTA™ chromatography system, both from Cytiva. This process was not only fundamental to the development of the lateral flow device but was also scalable, and so now supports full-scale manufacturing. Moreover, our lateral flow immunoassay development services were able to provide expertise and support across this client’s workflow, from initial development and clinical trials to manufacturing and commercialization.”

https://www.labroots.com/trending/clinical-and-molecular-dx/23005/accelerate-diagnostic-development-supplier

Check out 2&6s posts, woe, woe, and more woe...lol

f/m, 2&6 (tuan6) is back lol

@Troajan, this is from Oct Rns.Graphene Research Collaboration with Monash University, Australia



Tirupati Graphite plc, the fully integrated, revenue generating, specialist graphite producer and graphene and advanced materials developer, has entered into a research collaboration agreement with the Department of Material Sciences and Engineering at Monash University, Victoria, Australia ('Monash') to develop commercial applications for a range of graphene products in raw and recycled polymer nanocomposites and dispersions.



Overview

· Research focussed on enhancing thermal, electrical, and mechanical properties of various polymers and preparation of dispersions for developing a range of commercial products:

o Graphene Dispersions: To achieve stable dispersion of Graphene Oxide and Reduced Graphene Oxide ('GO' and 'rGO') in liquids for use in a suite of applications like concrete, acoustics and composites;

o Conductive / High Strength Polymers: Optimising use of GO and rGO in polymers to enhance strength, thermal, electrical and other mechanical properties to manufacture new age plastics with potential use in acoustics, aerospace, defence, automotive, charge insulation and other applications;

o Graphene - Plastic Railway Sleepers: Development of a graphene-polymer composite using recycled plastic and GO for potential use in railway sleepers with Monash Institute of Railway Technology joining this activity;

o Smart Skin & Performance Coatings: Development of a smart skin (protecting and self-healing coating) and performance coatings using GO and rGO for use as anti-corrosive coatings on structural steel, marine, defence applications and more; and

o Recyclability: Assessment of recyclability cycles of these graphene-polymer composites for ability to utilise recycled polymers.

· The research will further the previous findings from research conducted by Tirupati adviser, Dr. Matthieu Gresil, using rGO, which established substantial improvements in target polymer properties using rGO with formation of stable homogeneous composite

· The collaboration complements Tirupati's internal research in advanced materials and composites utilising Monash's extensive capabilities on polymer and plastic nanocomposites with targeted product development for applications in defence, transportation, and construction industries.

· The Company shall own all the intellectual property outcome from the collaboration with Monash retaining liberty for use in academic publication and further research purposes.



Shishir Poddar, CEO of Tirupati Graphite, said, "The evolution of new age materials to improve energy efficiency, reduce energy and materials consumption and increase the lifespan of conventional materials, is an important constituent for reducing emissions and mitigating climate risk. Accordingly, we are delighted to be working with Monash, which will enable us to add polymer nanocomposites to our new age materials portfol

Big shout out for Graphene on sky climate show.

Nice buy though, i have a lot of faith in TGR.

Fair enough cag, although i can`t agree. Almost completely the opposite :)

"never buy a falling share and never sell a riser"

Who on earth told you that ?

http://malawi.mynews.club/news/mkango-commences-final-stage-of-hydrometallurgy-piloting-for-the-songwe-hill-rare-earths-project-in-malawi.html

Well worth going on Leeds uni website. Type in Affimers in search bar, lots of links to explore. Affimers everywhere.

From only a month ago,

“The complexity of the task makes predicting the timeframe for publishing new results and operational updates difficult. We have over 20 world-class experts working in our R&D team to achieve these results. We will endeavour to communicate more frequently with our shareholders. We strongly believe that our efforts are taking QBT into a new direction of Bitcoin mining and ask for shareholders’ patience until these efforts are rewarded by success.”